CD20 — Targeted Therapies, Trials & Pipeline
A B-cell surface antigen targeted by antibodies and bispecifics in B-cell lymphomas and leukemias.
Approved drugs targeting CD20
epcoritamab
·
glofitamab
·
mosunetuzumab
·
obinutuzumab
·
ofatumumab
·
Rituximab
Investigational pipeline agents
odronextamab
Landmark trials
GALLIUM